User: Guest  Login
Document type:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
Author(s):
Golan, Talia; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; Hall, Michael J; Park, Joon-Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do-Youn; Reinacher-Schick, Anke; Tortora, Giampaolo; Algül, Hana; O'Reilly, Eileen M; McGuinness, David; Cui, Karen Y; Schlienger, Katia; Locker, Gershon Y; Kindler, Hedy L 
Title:
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. 
Abstract:
BACKGROUND: Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease tha...    »
 
Journal title abbreviation:
N Engl J Med 
Year:
2019 
Journal volume:
381 
Journal issue:
Pages contribution:
317-327 
Fulltext / DOI:
Print-ISSN:
0028-4793 
TUM Institution:
Lehrstuhl für Tumormetabolismus (Prof. Algül)